Celcuity Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Celcuity Inc. (NASDAQ:CELC) have earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $30.17.

Several research analysts have recently issued reports on CELC shares. Needham & Company LLC raised their target price on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th.

Celcuity Stock Down 2.7 %

Shares of NASDAQ:CELC opened at $12.25 on Friday. Celcuity has a 12 month low of $10.35 and a 12 month high of $22.19. The firm has a market cap of $454.84 million, a P/E ratio of -4.69 and a beta of 0.73. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $12.31 and its two-hundred day moving average price is $14.45.

Institutional Trading of Celcuity

Several hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC bought a new position in Celcuity during the 3rd quarter worth about $33,000. Prospera Private Wealth LLC bought a new position in shares of Celcuity during the 3rd quarter worth approximately $35,000. Values First Advisors Inc. acquired a new stake in shares of Celcuity in the third quarter valued at approximately $86,000. SG Americas Securities LLC bought a new stake in shares of Celcuity in the third quarter worth $119,000. Finally, Bleakley Financial Group LLC acquired a new position in Celcuity during the fourth quarter worth $146,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.